Tonghua Dongbao Medicines has begun the second phase of expanding its 3,000 kg recombinant human insulin (lyophilized powder) project. Meanwhile, the company reveals that it will invest 80 million yuan in the next half year to set up the new facility to output 30 million human insulin injections annually. Figures show that China's total insulin injections retailed last year reached 3 billion yuan or about 50 million doses, with 90 to 95 percent of the market dominated by pharmaceutical MNCs such as Novo Nordisk and Eli Lilly. Because of the considerable expense in promoting insulin injections, analysts believe Dongbao will face tough competition increasing its sales from the current 3 million injections to a possible 38 million injections. (Click here for more - Chinese Language)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.
The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.
The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.
